Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionSTEIGBIGEL, Roy T; COOPER, David A; KATLAMA, Christine et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 339-354, issn 0028-4793, 16 p.Article

Introduction of Ertapenem into a Hospital Formulary: Effect on Antimicrobial Usage and Improved In Vitro Susceptibility of Pseudomonas aeruginosaGOLDSTEIN, Ellie J. C; CITRON, Diane M; PERAINO, Victoria et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 12, pp 5122-5126, issn 0066-4804, 5 p.Article

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionCOOPER, David A; STEIGBIGEL, Roy T; SCHECHTER, Mauro et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 355-365, issn 0028-4793, 11 p.Article

Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II StudyGATELL, Jose M; KATLAMA, Christine; MEIBOHM, Anne R et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 53, Num 4, pp 456-463, issn 1525-4135, 8 p.Article

Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. CommentaryCOPLAN, Paul M; COOK, John R; CARIDES, George W et al.Clinical infectious diseases. 2004, Vol 39, Num 3, pp 426-436, issn 1058-4838, 11 p.Article

Random-Effects Meta-analysis of Inconsistent Effects: A Time for ChangeCORNELL, John E; MULROW, Cynthia D; LOCALIO, Russell et al.Annals of internal medicine. 2014, Vol 160, Num 4, pp 267-270, issn 0003-4819, 4 p.Article

Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactamSOLOMKIN, Joseph; TEPPLER, Hedy; GRAHAM, Donald R et al.Journal of antimicrobial chemotherapy (Print). 2004, Vol 53, pp ii51-ii57, issn 0305-7453, SUP2Article